610 / 1835
Untreated DLBCL
(n=1400)
CHOP
+ GA101
+ rituximab
R
Goya Study
E
NDPOINTS
1
o
:
PFS in FL population
2
o
:
•
PFS in whole population
•
PFS by Independent Review Committee (IRC)
•
ORR/CR rate at end of induction (with and without PET) Investigator
and
IRC
•
overall survival, EFS, disease-free survival (DFS), duration of response,
and time to next anti-lymphoma treatment between the two arms
•
Safety
•
patient-reported outcomes (PROs) in both arms